Reducing Cost Of Goods For Gene Therapy

The entire sector is undergoing rapid evolution, and novel methods, platforms, and solutions have emerged in the last three years. Given the various challenges faced by the cell and gene therapy manufacturing industry due to capacity shortage, high investment costs, and other factors, some innovative solutions have evolved, such as single-use systems and modular biomanufacturing facilities. These innovations have been directly associated with capital expenditure (Capex) benefits and other advantages.

There has been much progress in moving potentially life-saving gene therapies to the market, but they are extremely costly to produce. To address the need to reduce COGs, we invited a panel of industry experts to join our discussion.